These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14968085)

  • 1. [Monitoring the patient after treatment: angiographic aspects of recurrence and indications for retreatment].
    Coscas G; Coscas F; Soubrane G
    J Fr Ophtalmol; 2004 Jan; 27(1):81-92. PubMed ID: 14968085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term reaction of choroidal neovascularization and choriocapillaris to photodynamic therapy in age-related macular degeneration.
    Eter N; Vogel A; Inhetvin-Hutter C; Spitznas M
    Eur J Ophthalmol; 2003 Oct; 13(8):687-92. PubMed ID: 14620172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
    Verteporfin Roundtable Participants
    Retina; 2005; 25(2):119-34. PubMed ID: 15689800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.
    Eandi CM; Ober MD; Freund KB; Slakter JS; Yannuzzi LA
    Retina; 2007 Sep; 27(7):825-31. PubMed ID: 17891004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    ; ;
    Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration.
    Michels S; Wachtlin J; Gamulescu MA; Heimann H; PrĂ¼nte C; Inhoffen W; Krebs I; Schmidt-Erfurth U
    Ophthalmology; 2005 Dec; 112(12):2070-5. PubMed ID: 16225928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
    Kaiser PK;
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
    Barbazetto I; Burdan A; Bressler NM; Bressler SB; Haynes L; Kapetanios AD; Lukas J; Olsen K; Potter M; Reaves A; Rosenfeld P; Schachat AP; Strong HA; Wenkstern A; ;
    Arch Ophthalmol; 2003 Sep; 121(9):1253-68. PubMed ID: 12963608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
    Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
    Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ; Schmidt-Erfurth U
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin.
    Schmidt-Erfurth UM; Michels S
    Ophthalmology; 2003 Jul; 110(7):1306-14. PubMed ID: 12867383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy with verteporfin for retinal angiomatous proliferation.
    Boscia F; Parodi MB; Furino C; Reibaldi M; Sborgia C
    Graefes Arch Clin Exp Ophthalmol; 2006 Oct; 244(10):1224-32. PubMed ID: 16525824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.